← Eichor
Study identifier: NCT04270786 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Early De-escalation of Empirical Antibiotics Treatment for Neutropenic Fever

Condition: Safety Issues  ·  Sponsor: Shanghai Jiao Tong University School of Medicine

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

This is a randomized study to evaluate the safety and feasibility of early de-escalation of empirical antibiotics treatment in neutropenic fever patients undergoing hematopoietic stem cell transplantation (HSCT). In case of afebrile for 72 hours with empirical antibiotics treatment, patients will be randomized into 2 groups. In the early de-escalation group, antibiotics treatment will be stopped and prophylaxis with levofloxacin will be resumed. In the control group, the empirical treatment will continue until recovery of neutropenia or at least for 7 days.

This description comes directly from the study's public registry record.

Talk to the study team

Ling Wang  ·  86-21-64370045  ·  cclingjar@163.com

Jiong HU  ·  86-21-64370045  ·  hj10709@rjh.com.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Blood & Marrow Transplantation Center, RuiJin HospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04270786